$IMUX
Immunic Inc

2015 Q3 Form 10-Q Financial Statement

#000119312515281202 Filed on August 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.690M $3.530M $2.510M
YoY Change 4.67% 40.64% -0.79%
% of Gross Profit
Research & Development $9.646M $11.55M $9.125M
YoY Change -5.84% 26.52% 101.08%
% of Gross Profit
Depreciation & Amortization $325.0K $328.0K $246.0K
YoY Change 4.84% 33.33% 41.38%
% of Gross Profit
Operating Expenses $12.34M $15.08M $11.64M
YoY Change -3.71% 29.56% 64.77%
Operating Profit -$12.34M -$15.08M -$11.64M
YoY Change -3.71% 29.56% 64.77%
Interest Expense $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $35.00K -$28.00K $1.471M
YoY Change 191.67% -101.9% 60.07%
Pretax Income -$12.30M -$15.11M -$10.17M
YoY Change -3.91% 48.57% 65.64%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$12.30M -$15.11M -$10.17M
YoY Change -3.89% 48.58% 65.48%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$20.50M -$25.18M -$28.25M
COMMON SHARES
Basic Shares Outstanding 24.02M shares 24.01M shares 21.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.80M $71.90M $90.80M
YoY Change -24.4% -20.81% 119.32%
Cash & Equivalents $59.75M $71.95M $90.84M
Short-Term Investments
Other Short-Term Assets $2.900M $3.500M $2.600M
YoY Change -17.14% 34.62% 13.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $62.61M $75.45M $93.49M
YoY Change -24.19% -19.3% 113.45%
LONG-TERM ASSETS
Property, Plant & Equipment $4.163M $4.212M $3.264M
YoY Change 39.46% 29.04% 81.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $171.0K $214.0K $263.0K
YoY Change -34.98% -18.63% 31.5%
Total Long-Term Assets $4.334M $4.426M $3.527M
YoY Change 33.44% 25.49% 76.35%
TOTAL ASSETS
Total Short-Term Assets $62.61M $75.45M $93.49M
Total Long-Term Assets $4.334M $4.426M $3.527M
Total Assets $66.94M $79.87M $97.02M
YoY Change -22.01% -17.67% 111.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $549.0K $920.0K $1.461M
YoY Change -21.12% -37.03% -43.81%
Accrued Expenses $7.380M $8.852M $5.806M
YoY Change -1.99% 52.46% 205.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.119M $9.977M $7.561M
YoY Change -4.46% 31.95% -16.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $146.0K $159.0K $292.0K
YoY Change -48.41% -45.55%
Total Long-Term Liabilities $146.0K $159.0K $292.0K
YoY Change -48.41% -45.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.119M $9.977M $7.561M
Total Long-Term Liabilities $146.0K $159.0K $292.0K
Total Liabilities $8.265M $10.14M $7.853M
YoY Change -5.88% 29.07% -13.7%
SHAREHOLDERS EQUITY
Retained Earnings -$193.0M -$180.7M -$124.1M
YoY Change 41.0% 45.63%
Common Stock $2.000K $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.68M $69.74M $89.16M
YoY Change
Total Liabilities & Shareholders Equity $66.94M $79.87M $97.02M
YoY Change -22.01% -17.67% 111.83%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$12.30M -$15.11M -$10.17M
YoY Change -3.89% 48.58% 65.48%
Depreciation, Depletion And Amortization $325.0K $328.0K $246.0K
YoY Change 4.84% 33.33% 41.38%
Cash From Operating Activities -$12.04M -$15.11M -$9.880M
YoY Change 7.6% 52.94% 68.89%
INVESTING ACTIVITIES
Capital Expenditures -$310.0K -$1.310M -$240.0K
YoY Change -3.13% 445.83% -45.45%
Acquisitions
YoY Change
Other Investing Activities $340.0K $120.0K -$230.0K
YoY Change -254.55% -152.17% -104.93%
Cash From Investing Activities $40.00K -$1.190M -$470.0K
YoY Change -107.41% 153.19% -111.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -190.0K 0.000 55.14M
YoY Change 1800.0% -100.0% 72.85%
NET CHANGE
Cash From Operating Activities -12.04M -15.11M -9.880M
Cash From Investing Activities 40.00K -1.190M -470.0K
Cash From Financing Activities -190.0K 0.000 55.14M
Net Change In Cash -12.19M -16.30M 44.79M
YoY Change 3.83% -136.39% 47.87%
FREE CASH FLOW
Cash From Operating Activities -$12.04M -$15.11M -$9.880M
Capital Expenditures -$310.0K -$1.310M -$240.0K
Free Cash Flow -$11.73M -$13.80M -$9.640M
YoY Change 7.91% 43.15% 78.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Share Price
SharePrice
7.55
CY2015Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under Shelf Registration Statement
MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement
75000000
CY2015Q2 vtl Maximum Aggregate Offering Price Of Securities
MaximumAggregateOfferingPriceOfSecurities
200000000
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedUnderShelfRegistrationStatement
2500000 shares
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24015761 shares
CY2014Q1 us-gaap Share Price
SharePrice
11.30
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90840000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3258417 shares
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
95.21
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.07
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24014454 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1014780 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.96
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2963920 shares
CY2015Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250646 shares
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3196504 shares
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
501000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2085000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
69736000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8852000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180697000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79872000
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4523843 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24014454 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.80
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
159000
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
250343000
CY2015Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
133000
CY2015Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
205000
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
159000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
920000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7359000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9977000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
88000
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
42433566
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
214000
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
42476328
CY2015Q2 us-gaap Assets
Assets
79872000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4212000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
75446000
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1417000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2083000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71946000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11571000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42936265
CY2015Q2 vtl Accrued Clinical Costs
AccruedClinicalCosts
6266000
CY2015Q2 vtl Sale Of Securities Under Public Offerings
SaleOfSecuritiesUnderPublicOfferings
0
CY2013Q4 us-gaap Share Price
SharePrice
5.93
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38186000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3210693 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.54
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23982786 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23982786 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
249000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2554000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
97563000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
241000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
248305000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
126000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
250000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
241000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1153000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8875000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150833000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108082000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6778000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10278000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
89000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
198000
CY2014Q4 us-gaap Assets
Assets
108082000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3068000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
104816000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1592000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
986000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102238000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9846000
CY2014Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
6072000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19242000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.05
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9273672 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1045000
us-gaap Net Income Loss
NetIncomeLoss
-20915000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30069000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
215000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-23515000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2600000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
271000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20916000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
294000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
52000
us-gaap Share Based Compensation
ShareBasedCompensation
1108000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4410000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
393000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
52654000
us-gaap Operating Expenses
OperatingExpenses
23515000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1316000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18167000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
73213000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18345000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2552000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
4744000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5170000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
110796000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
55046000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
337000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
543000
vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
2600000
vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
52000
vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
0
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28623000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M28D
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M29D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.98
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
43332 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.87
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.60
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</p> </div>
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
31668 shares
dei Trading Symbol
TradingSymbol
VTL
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23984629 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
122724 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1980000
us-gaap Net Income Loss
NetIncomeLoss
-29864000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29864000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
921000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
51000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29896000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
418000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30292000
us-gaap Operating Expenses
OperatingExpenses
29896000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1805000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-175000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
32000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29865000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
us-gaap Investment Income Interest
InvestmentIncomeInterest
23000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
64000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2000
us-gaap Share Based Compensation
ShareBasedCompensation
1801000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
135000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23299000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-125000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
186000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6597000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-62000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
622000
vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
52000
vtl Operating Lease Agreements Expiration Year
OperatingLeaseAgreementsExpirationYear
2017
vtl Increase Decrease In Other Liabilities
IncreaseDecreaseInOtherLiabilities
-76000
vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
141000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17888171 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-10167000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16251000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11638000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
vtl Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1471000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10167000
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2014Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1362000
CY2014Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
210000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
11638000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9125000
CY2014Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
4722000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2513000
CY2014Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
246000
CY2014Q2 vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
1472000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23996527 shares
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-15106000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15106000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15078000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15107000
CY2015Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000
CY2015Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
193000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
15078000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11545000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3533000
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
328000

Files In Submission

Name View Source Status
0001193125-15-281202-index-headers.html Edgar Link pending
0001193125-15-281202-index.html Edgar Link pending
0001193125-15-281202.txt Edgar Link pending
0001193125-15-281202-xbrl.zip Edgar Link pending
d937753d10q.htm Edgar Link pending
d937753dex311.htm Edgar Link pending
d937753dex312.htm Edgar Link pending
d937753dex321.htm Edgar Link pending
d937753dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-20150630.xml Edgar Link completed
vtl-20150630.xsd Edgar Link pending
vtl-20150630_cal.xml Edgar Link unprocessable
vtl-20150630_def.xml Edgar Link unprocessable
vtl-20150630_lab.xml Edgar Link unprocessable
vtl-20150630_pre.xml Edgar Link unprocessable